Grit Bio Inc

NEW YORK, NY · Biotech · Private

Inhaled anti-viral therapeutic delivering salivary protein to block coronavirus replication in the lung

Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Development of a novel peptide inhibitor of coronavirus papain-like protease as a prophylactic and anti-viral therapeutic for COVID19, administered by inhalation$255,981
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3323Clasp Therapeutics——
3324Cgenetech, Inc.——
3325HSIRI THERAPEUTICS——
3326Grit Bio Inc——
3327SYNAPTEX, LLC——
3328SURFACE BIOADVANCES, INC.——
3329LoQus23 Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.